Ginkgo Bioworks Holdings, Inc.
DNA
$6.79
-$0.45-6.22%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -46.80% | -42.44% | -34.11% | -26.57% | 14.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.80% | -42.44% | -34.11% | -26.57% | 14.06% |
| Cost of Revenue | -19.86% | -27.53% | -33.62% | -23.22% | -14.71% |
| Gross Profit | -51.47% | -45.58% | -34.23% | -27.36% | 21.16% |
| SG&A Expenses | -14.26% | -21.23% | -28.15% | -29.51% | -34.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.16% | -31.41% | -37.17% | -36.82% | -42.81% |
| Operating Income | -1.34% | 24.86% | 38.61% | 40.95% | 58.25% |
| Income Before Tax | 1.94% | 37.23% | 45.42% | 50.07% | 66.43% |
| Income Tax Expenses | 33.63% | -138.15% | -74.74% | -47.44% | -89,600.00% |
| Earnings from Continuing Operations | 1.85% | 37.39% | 45.52% | 50.12% | 66.53% |
| Earnings from Discontinued Operations | 127.68% | -78.29% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.74% | 35.52% | 42.83% | 47.86% | 64.89% |
| EBIT | -1.34% | 24.86% | 38.61% | 40.95% | 58.25% |
| EBITDA | -6.06% | 25.59% | 41.26% | 43.68% | 61.20% |
| EPS Basic | 14.50% | 40.42% | 46.85% | 51.74% | 67.53% |
| Normalized Basic EPS | 0.12% | 28.02% | 42.12% | 43.70% | 62.09% |
| EPS Diluted | 14.43% | 40.39% | 46.87% | 51.79% | 67.56% |
| Normalized Diluted EPS | 0.12% | 28.01% | 42.11% | 43.68% | 62.08% |
| Average Basic Shares Outstanding | 8.93% | 7.31% | 6.88% | 7.57% | 7.74% |
| Average Diluted Shares Outstanding | 8.93% | 7.30% | 6.86% | 7.54% | 7.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |